Dr. Judith Campisi — Professor of Biogerontology – Buck Institute for Research on Aging
Discussion of the Future of \”Seno-Therapeutic Development\” — Dr. Judith Campisi PhD, Professor, Buck Institute for Research on Aging.
Dr. Judith Campisi, PhD (https://www.buckinstitute.org/lab/campisi-lab/) is a biochemist, cell biologist, and Professor of Biogerontology at the Buck Institute for Research on Aging.
Dr. Campisi earned a PhD in Biochemistry at the State University of New York, Stony Brook. She completed her postdoctoral work in cell cycle regulation in the Dana-Farber Cancer Institute at Harvard Medical School. She studied cellular senescence as an assistant and associate Professor at Boston University Medical School. She soon realized that senescent cell also contributes to aging. In 1991, she joined the Lawrence Berkeley National Laboratory in California as a scientist working with Dr. Mina Bissell. She opened a second lab at the Buck Institute in 2000. In both institutions, Dr. Campisi developed a program that aimed to better understand the relationship between ageing and age-related diseases, with a focus on the interface of cancer and aging.
Dr. Campisi has been a member of the National Academy of Sciences since 1989 and is also a fellow of the American Association for the Advancement of Science.
Dr. Campisi is the recipient of numerous awards for her work, including MERIT Awards from the National Institute on Aging, Gerontological Society of America and American Federation for Aging Research, as well as awards from AlliedSignal Corporation and the Gerontological Society of America. She has received the Longevity Prize from the IPSEN Foundation as well as the Bennett Cohen Award from the University of Michigan and the Schober Award from Halle University. She is also the first winner of the Olav Thon Foundation International Prize in Natural Sciences and Medicine. Dr. Campisi is currently a member of the advisory committees for Alliance for Aging Research and Progeria Research Foundation. She also serves as NIA’s Intervention Testing Program. She also serves as an editor for over a dozen peer reviewed journals. Dr. Campisi founded Unity Biotechnology in California, which focuses on the development of senolytic therapy for age-related diseases. She served on the scientific boards of Geron Corporation Sierra BioScience and Sangamo Biosciences.
Source:
